Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
16 May 2024
|
|
N 14:41 | Leniolisib 3 changes history +359 [Alen Antony (3×)] | |||
|
|
14:41 (cur | prev) +2 Alen Antony talk contribs | ||||
|
|
14:40 (cur | prev) −2 Alen Antony talk contribs | ||||
| N |
|
14:40 (cur | prev) +359 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=leniolisib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. |adverseReactions=headache, sinusitis, and {{atopic dermatitis}}. |brandNames=JOENJA }}") | |||
|
|
14:34 | Trofinetide 6 changes history +5,945 [Alen Antony (6×)] | |||
|
|
14:34 (cur | prev) +1,803 Alen Antony talk contribs | ||||
|
|
14:19 (cur | prev) −1 Alen Antony talk contribs Tag: Manual revert | ||||
|
|
03:47 (cur | prev) +1 Alen Antony talk contribs | ||||
|
|
03:46 (cur | prev) +2,158 Alen Antony talk contribs | ||||
|
|
03:29 (cur | prev) +912 Alen Antony talk contribs | ||||
|
|
03:09 (cur | prev) +1,072 Alen Antony talk contribs | ||||
|
|
N 10:15 | Avacincaptad pegol 2 changes history +3,387 [Muhammad Waleed (2×)] | |||
|
|
10:15 (cur | prev) +132 Muhammad Waleed talk contribs | ||||
| N |
|
10:11 (cur | prev) +3,255 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=Avacincaptad Pegol |drugClass=Avacincaptad pegol is a complement C5 protein inhibitor |indication=IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |adverseReactions=Common adverse reactions (≥5% of patients) include conjunctival hemorrhage, increased intraocular pressure, and endophthalmitis. |blackBoxWarningTitle=There is no black box warning listed for IZERV...") | |||
|
|
10:14 | Talquetamab-tgvs 2 changes history +2,312 [Muhammad Waleed (2×)] | |||
|
|
10:14 (cur | prev) +505 Muhammad Waleed talk contribs | ||||
|
|
09:28 (cur | prev) +1,807 Muhammad Waleed talk contribs | ||||
| 09:31 | Upload log Muhammad Waleed talk contribs uploaded File:Talvey (talquetamab-tgvs).png (image for the drug Talvey) | ||||
.png){kind=link}
|
|
07:07 | User:AED 4 changes history +102 [Alara E. Dagsali (4×)] | |||
|
|
07:07 (cur | prev) +21 Alara E. Dagsali talk contribs | ||||
|
|
06:42 (cur | prev) +24 Alara E. Dagsali talk contribs | ||||
|
|
06:33 (cur | prev) +27 Alara E. Dagsali talk contribs | ||||
|
|
06:22 (cur | prev) +30 Alara E. Dagsali talk contribs | ||||
|
|
N 07:06 | Diclofenac Patch 2 changes history +48,613 [Alara E. Dagsali (2×)] | |||
|
|
07:06 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
07:06 (cur | prev) +48,610 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr...") | |||
|
|
N 06:42 | Cortisone Acetate 2 changes history +14,098 [Alara E. Dagsali (2×)] | |||
|
|
06:42 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
06:42 (cur | prev) +14,095 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen...") | |||
|
|
N 06:33 | Clocortolone Pivalate 2 changes history +4,446 [Alara E. Dagsali (2×)] | |||
|
|
06:33 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
06:32 (cur | prev) +4,443 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed...") | |||
|
|
N 06:21 | Scorpion 2 changes history +12,448 [Alara E. Dagsali (2×)] | |||
|
|
06:21 (cur | prev) +30 Alara E. Dagsali talk contribs | ||||
| N |
|
06:20 (cur | prev) +12,418 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u...") | |||
15 May 2024
|
|
20:44 | Medication reconciliation 2 changes history +536 [Badgettrg (2×)] | |||
|
|
20:44 (cur | prev) +1 Badgettrg talk contribs (→Frequency of reconciliation errors) | ||||
|
|
20:43 (cur | prev) +535 Badgettrg talk contribs | ||||
| 14:58 | Vamorolone diffhist +11,928 Rafael Garcia talk contribs | ||||
|
|
14:21 | User:Archana.vajjala 2 changes history −24 [Archana.vajjala (2×)] | |||
|
|
14:21 (cur | prev) −22 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
12:16 (cur | prev) −2 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
N 10:59 | Lodoxamide 2 changes history +6,537 [Alara E. Dagsali (2×)] | |||
|
|
10:59 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
10:58 (cur | prev) +6,534 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...") | |||
|
|
04:40 | Trofinetide 2 changes history +176 [Alen Antony (2×)] | |||
|
|
04:40 (cur | prev) +41 Alen Antony talk contribs | ||||
|
|
04:40 (cur | prev) +135 Alen Antony talk contribs | ||||
|
|
04:28 | Fezolinetant 8 changes history +4,781 [Alen Antony (8×)] | |||
|
|
04:28 (cur | prev) +1,695 Alen Antony talk contribs | ||||
|
|
04:21 (cur | prev) +1,499 Alen Antony talk contribs | ||||
|
|
03:44 (cur | prev) +174 Alen Antony talk contribs | ||||
|
|
03:37 (cur | prev) +19 Alen Antony talk contribs | ||||
|
|
02:46 (cur | prev) +589 Alen Antony talk contribs | ||||
|
|
02:24 (cur | prev) +234 Alen Antony talk contribs | ||||
|
|
01:32 (cur | prev) +512 Alen Antony talk contribs | ||||
|
|
01:09 (cur | prev) +59 Alen Antony talk contribs | ||||
14 May 2024
|
|
21:44 | Fezolinetant 2 changes history +817 [Alen Antony (2×)] | |||
|
|
21:44 (cur | prev) +723 Alen Antony talk contribs | ||||
|
|
21:34 (cur | prev) +94 Alen Antony talk contribs | ||||
| 04:55 | Somatrogon-ghla diffhist +52 Kosar Doraghi talk contribs | ||||
13 May 2024
| N 23:48 | Fezolinetant diffhist +84 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}") | ||||
|
|
N 23:46 | Nirsevimab-alip 2 changes history +5,780 [Alen Antony (2×)] | |||
|
|
23:46 (cur | prev) +3,844 Alen Antony talk contribs | ||||
| N |
|
14:50 (cur | prev) +1,936 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Nirsevimab-alip |aOrAn=a |drugClass=human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody |indicationType=prevention |indication=Respiratory Syncytial Virus (RSV) lower respiratory tract disease for neonates and infants born during or entering their first RSV season and children up to 24 years of age who are vulnerable to severe RSV disease in their second RSV season. |adverseReactions=rashes and injection...") | |||
| N 20:38 | Talquetamab-tgvs diffhist +2,766 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent...") | ||||
| 14:23 | Non-alcoholic fatty liver disease epidemiology and demographics diffhist +1,197 Badgettrg talk contribs (→Overview) | ||||
12 May 2024
|
|
23:08 | Vitamin D 2 changes history +1,636 [Badgettrg (2×)] | |||
|
|
23:08 (cur | prev) +503 Badgettrg talk contribs (→Medical uses) | ||||
|
|
23:00 (cur | prev) +1,133 Badgettrg talk contribs (→Role in depression prevention) | ||||
| 21:59 | Systematic review diffhist +3,699 Badgettrg talk contribs (→Living systematic reviews) | ||||
| 21:06 | Template:KDRG diffhist +47 Kosar Doraghi talk contribs | ||||
|
|
N 21:04 | Somatrogon-ghla 2 changes history +12,691 [Kosar Doraghi (2×)] | |||
|
|
21:04 (cur | prev) +215 Kosar Doraghi talk contribs | ||||
| N |
|
05:30 (cur | prev) +12,476 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.con] |genericName=somatrogon-ghla |aOrAn=a |drugClass=human growth hormone analog |indicationType=treatment |indication=pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone |hasBlackBoxWarning=Yes |adverseReactions=injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, v...") | |||
| 20:52 | Chronic renal failure overview diffhist +13,854 Kosar Doraghi talk contribs | ||||
|
|
19:35 | (Upload log) [Kosar Doraghi (8×)] | |||
|
|
19:35 Kosar Doraghi talk contribs uploaded File:IMG 1208.jpeg | ||||
|
|
19:33 Kosar Doraghi talk contribs uploaded File:IMG 1207.jpeg | ||||
|
|
19:32 Kosar Doraghi talk contribs uploaded File:IMG 1204.jpeg | ||||
|
|
19:30 Kosar Doraghi talk contribs uploaded File:IMG 1202.jpeg | ||||
|
|
19:28 Kosar Doraghi talk contribs uploaded File:IMG 1200.jpeg | ||||
|
|
19:24 Kosar Doraghi talk contribs uploaded File:IMG 1214.jpeg | ||||
|
|
05:15 Kosar Doraghi talk contribs uploaded File:IMG 1198.jpeg | ||||
|
|
05:13 Kosar Doraghi talk contribs uploaded File:IMG 1215.jpeg | ||||
11 May 2024
|
|
22:32 | Mirikizumab-mrkz 3 changes history +5,248 [Rithish Nimmagadda (3×)] | |||
|
|
22:32 (cur | prev) +13 Rithish Nimmagadda talk contribs | ||||
|
|
22:31 (cur | prev) 0 Rithish Nimmagadda talk contribs | ||||
|
|
22:26 (cur | prev) +5,235 Rithish Nimmagadda talk contribs | ||||
| N 20:21 | Elfabrio diffhist +3,351 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio...") | ||||
| N 19:36 | Exxua diffhist +44 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}") | ||||
|
|
19:09 | Facioscapulo-humeral dystrophy 8 changes history +2,898 [Dj (8×)] | |||
|
|
19:09 (cur | prev) +29 Dj talk contribs (→History) | ||||
|
|
18:59 (cur | prev) +191 Dj talk contribs | ||||
|
|
18:45 (cur | prev) +637 Dj talk contribs (→Pathophysiology) | ||||
|
|
18:41 (cur | prev) +138 Dj talk contribs | ||||
|
|
17:59 (cur | prev) +789 Dj talk contribs (→Classification) | ||||
|
|
17:52 (cur | prev) −5 Dj talk contribs | ||||
|
|
17:51 (cur | prev) +363 Dj talk contribs | ||||
|
|
17:43 (cur | prev) +756 Dj talk contribs | ||||
| 12:13 | User:Archana.vajjala diffhist +62 Archana.vajjala talk contribs (→Interests) | ||||
10 May 2024
| 21:12 | Stress ulcer diffhist +1,682 Badgettrg talk contribs (→Drug classes and options available) | ||||
|
|
19:11 | Sotagliflozin 3 changes history +2,207 [Alen Antony (3×)] | |||
|
|
19:11 (cur | prev) +829 Alen Antony talk contribs | ||||
|
|
18:12 (cur | prev) +833 Alen Antony talk contribs | ||||
|
|
17:54 (cur | prev) +545 Alen Antony talk contribs | ||||